Abstract. The hypothesis of the present study was that a GnRH agonist application at early pregnancy would alter the pattern of the key reproductive hormones LH and FSH, and subsequently that of estradiol (E2) and especially progesterone (P4), and improve the conditions for embryo survival in early pregnant gilts. Therefore, the endocrine effects of a GnRH agonist (GnRHa) application to gilts (n=11 GnRHa treated, n=9 saline Controls) were studied in blood samples from the Vena cava caudalis. GnRHa injected on Day 12 after insemination induced elevated (P<0.01) LH and FSH levels for at least 180 min. However, subsequent LH concentrations were not altered up to Day 21 of pregnancy. LH pulse number, estimated in 6-h period samples on Days 13, 15 and 17, was not influenced by treatment and pregnancy. LH pulse amplitude was decreased (P<0.05) on Days 13 to 17 in pregnant gilts of both groups, but not in nonpregnant animals. In pregnant GnRHa-treated gilts, the basal LH level was elevated compared with the Controls (P<0.01). Additionally, differences (P<0.05) in basal LH were present between the pregnant and nonpregnant animals. The P4 and E2 secretion pattern was not affected by GnRHa. P4 concentrations increased (P<0.01) from Day 10 to Day 14 regardless of the treatment. P4 revealed a pulse-like pattern, but without a definite relation to the LH pulse characteristics. Also, pregnancy rate (73 vs. 67%) and the number of fetuses (12.8 ± 2.3 vs. 11.6 ± 2.3) were unaffected in the treated and Control gilts, respectively. The present study did not confirm the initial hypothesis that a GnRHamediated LH effect could alter ovarian steroid secretion and favorably support early embryo development and pregnancy outcome. Key words: GnRH-agonist, LH, Pig, Pregnancy, Progesterone (J. Reprod. Dev. 57: [242][243][244][245][246][247][248] 2011) rogesterone from the developing corpus luteum (CL) is the most important driver of endometrial secretion and receptivity for early conceptus development and implantation in pigs [1, 2] . About 30% of porcine conceptuses are lost during the peri-implantation period [3] , and this period is susceptible to a lack of P4. It has been shown that a concentration of 4 ng/ml P4 in peripheral blood appears to be minimum required for maintenance of pregnancy [4] . Attempts have been undertaken to improve pregnancy rate or reduce pregnancy losses in pigs by steroid or gonadotropin application [5] [6] [7] . Since steroid treatment may improve litter size [8, 9] , the question is whether luteal P4 secretion can be enhanced by GnRH-induced LH stimulation. This is because LH is considered to be essential in pigs for support of luteal P4 production and pregnancy outcome as demonstrated by passive immunization with anti-LH serum or blockage of LH secretion and regulation of ovarian function by a GnRH antagonist [10, 11] .
(J. Reprod. Dev. 57: [242] [243] [244] [245] [246] [247] [248] 2011) rogesterone from the developing corpus luteum (CL) is the most important driver of endometrial secretion and receptivity for early conceptus development and implantation in pigs [1, 2] . About 30% of porcine conceptuses are lost during the peri-implantation period [3] , and this period is susceptible to a lack of P4. It has been shown that a concentration of 4 ng/ml P4 in peripheral blood appears to be minimum required for maintenance of pregnancy [4] . Attempts have been undertaken to improve pregnancy rate or reduce pregnancy losses in pigs by steroid or gonadotropin application [5] [6] [7] . Since steroid treatment may improve litter size [8, 9] , the question is whether luteal P4 secretion can be enhanced by GnRH-induced LH stimulation. This is because LH is considered to be essential in pigs for support of luteal P4 production and pregnancy outcome as demonstrated by passive immunization with anti-LH serum or blockage of LH secretion and regulation of ovarian function by a GnRH antagonist [10, 11] .
The hypothesis of the present study was that a single GnRH agonist application, given on Day 12 after insemination, would alter the pattern of the key reproductive hormones LH and FSH, and subsequently that of E2 and especially of P4, and possibly improve the conditions for embryo survival in early pregnant gilts. We decided to evaluate the effect of a single GnRHa administration on Day 12 of pregnancy on luteal P4 release by sampling blood near the ovary, via Vena cava caudalis. The reasons for this were that the period between Days 11-13 is important for establishment of pregnancy [12] and Vena cava sampling makes it possible to study P4 secretion by the ovary before its metabolism in the liver [13, 14] .
Materials and Methods

Animals and animal treatment
All procedures involving animal handling and treatment were approved by the Committee for Animal Use and Care of the Agricultural Ministerial Department of Mecklenburg-Vorpommern, Germany (approval: LVL-MV/TSD/7221.3-1.1-055/03). Altogether, 20 Landrace gilts (9 months, with body weights of 136 ± 12 kg) were included in the trial. Estrus was synchronized in all gilts by 15 days of feeding with Regumate ® (16 mg altrenogest/day/gilt; Janssen-Cilag GmbH, Neuss, Germany). Twenty-four hours after the last Regumate ® feeding (0800 h), each animal received a single intramuscular injection of 850 IU equine chorionic gonadotropin (eCG; Pregmagon ® , IDT Biologika, Dessau-Tornau, Germany). Ovulation was induced 80 h later by administration of 500 IU human chorionic gonadotropin (hCG; Ovogest ® , Intervet, Unterschleißheim, Germany). All gilts were fixed-time inseminated 24 and 38 h after administration of hCG. The day of 2 nd insemination corresponded to Day 1 of pregnancy.
Gilts (n=11) were injected on Day 12 of pregnancy with 50 μg of the GnRH agonist Gonavet ® (D-Phe 6 -GnRH; Veyx, Schwarzenborn, Germany; Group GnRHa); the control animals (n=9; Group Control) received saline.
All gilts were surgically fitted with an indwelling vein catheter by placement into the Vena cava caudalis via the Vena saphena lateralis within the last three days of altrenogest treatment. Catheterization of the caudal vena cava [14] was adapted to the method of Benoit and Dailey [15] . Briefly, the skin was incised approximately 3 cm dorsal to the hock and 2 cm lateral to the Achilles tendon of the right rear leg. Thereafter, the subcutaneous fat was separated, and the Vena saphena was isolated by blunt dissection. Two ligatures were placed around the vessel to maintain slight traction. A small transversal incision was made in the vein, and a silicon catheter (1.6 mm ID, 3.2 mm OD; AMT Düsseldorf, Germany) was inserted up to before a point that was marked 54 cm from the tip. Catheters were secured with two ligatures around the vein, and a distal ligature was used to tie off the vein. The free end of the catheter was guided in a slight loop subcutaneously to the back and placed in a cotton bag.
Blood and tissue collection
Blood samples (each 10 ml) were collected from vena cava catheters in plastic syringes containing EDTA-potassium as an anticoagulant (KABE, Germany), three times a day (0800, 1200 and 1600 h) on Days 3 to 21 and at 10-min intervals for a 6-h period (0800 to 1400 h) on Days 11, 13, 15 and 17. On treatment Day 12, sampling was performed immediately before GnRHa application (0800 h), at in 30-min intervals thereafter and hourly between 1000 and 1600 h.
Blood samples were centrifuged immediately at 1,800 g for 15 min. Plasma aliquots were stored at -20 C until analyses. After every blood collection, the catheter was filled with 3 ml of 3% sodium citrate. Prior to blood collection, the citrate within the catheter together with the first 3 ml of blood was discarded.
Ovarian features and pregnancies were observed at slaughter on Day 27. At this time, the reproductive tract was removed, and the number of CLs and fetuses was recorded.
Luteinizing hormone assay
LH was determined by a sandwich-type electrochemiluminescence immunoassay (ECLIA) [16] . The standard porcine LH (pLH iodination grade) was provided by Biotrend (Cologne, Germany), and the polyclonal rabbit-anti porcine LH (AFP15103194) was generously donated by NIDDK. Labeled monoclonal antibody (25 μl) and polyclonal antibody (50 μl) were allowed to bind to the hormone (standard/sample, 20 μl). The standard curve was started at 12.8 ng/ml and diluted through to 0.025 ng/ml. After overnight incubation, a "second" antibody, sheep anti-rabbit IgG coupled to magnetic beads (50 μl; Dynal, Oslo, Norway), was added. Finally, measurement of chemiluminescence was performed in an Origen TM 1.5 analyzer (IGEN, Gaithersburg, MD, USA). The sensitivity of the method was calculated to be 0.03 ng/ml. The intra-and interassay coefficients of variation (CV) were 6.0 and 8.4%, respectively.
Follicle-stimulating hormone assay
FSH concentrations were determined by RIA [17] . A specific antiserum (AFP2062096) and a highly purified pFSH standard (AFP10640B) used for radioiodination and calibration were obtained from NIDDK. The intra-and interassay CVs were 4.1 and 8.2%, respectively. The lower limit of sensitivity was 0.04 ng/ml.
Progesterone assay
The plasma concentrations of progesterone (P4) were measured by a direct 3 H-RIA in 10-μl duplicates as described previously [16] . The range of the standard curve was from 6.25 to 1,600 pg/ml. The incubation steps were performed at 37 C for 30 min and at 4 C for 2 h. The B/F separation was performed by the dextran-charcoal method. Counting of radioactivity was made by a Liquid Scintillation Counter with integrated RIA program (Tri-Carb 2900TR; Perkin-Elmer, Rodgau, Germany). The intra-and interassay CVs were 7.6 and 9.8%, respectively.
Estradiol-17β assay
The analysis of plasma estradiol (E2) was performed by a modified 3 H-RIA after ethyl ether extraction of 100-μl samples in duplicate [18] . The antibody raised in rabbits and purified by chromatography was used at a titer of 1:55,000 together with [2, 4, 6, H]-estradiol from GE Healthcare (Freiburg, Germany). The incubation steps and counting procedure were the same as for P4. The sensitivity of the RIA was 3 pg/ml. The intra-and interassay CVs were 6.9 and 9.9%, respectively.
Statistical analysis
The data were evaluated by repeated measures analysis of variance (ANOVA) using the MIXED procedure of the SAS/STAT software in the SAS System for Windows, release 9.2 (SAS Institute Inc. 2008). The ANOVA model for the response variable P4 included the fixed effects treatment group (levels: GnRHa, Control), pregnancy (levels: pregnant, non-pregnant), day (levels: Day 10 to Day 21), time (levels: 0800, 1200, 1600 h) and their interactions. Repeated measures on animals (day, time) were taken into account.
The ANOVA models for the response variables LH, FSH, P4 and E2 on treatment Day 12 contained the fixed effects of the treatment group (levels: GnRHa, Control), pregnancy (levels: pregnant, non-pregnant), the repeated factor time (levels: 0800, 0830, 0900, 0930 h and hourly between 1000 and 1600 h) and their interactions. In addition, least squares means ± SE were calculated and pairwise tested for each effect in the model using the Tukey procedure for all pairwise multiple comparisons and the Dunnett procedure for comparisons of the time levels with the 0800 h level.
The number of LH pulses, LH pulse amplitudes and mean and basal LH concentrations on Days 11, 13, 15 and 17 were calculated by PULSAR [19] . The following G-values were used: 3.8 for G1, 3.2 for G2, 2.7 for G3, 2.4 for G4 and 1.8 for G5. The respective secretion parameters were considered using a 10% criterion of variation and the appropriate assay parameters (sensitivity and frequency of sampling).
P4 pulses were analyzed on Days 11, 13, 15 and 15, respectively, and identified as described by Virolainen et al. [13] . A pulse was defined as at least two consecutive samples that exceeded the basal level by more than three standard deviations and in which the peak concentration occurred within two subsequent sampling intervals. The basal P4 concentration in the caval vein was defined as the mean of three consecutive samples preceding and following each suspect P4 pulse.
Results
Clinical data
Altogether, 20 gilts fitted with caval vein catheters were used for blood sampling for the whole experimental period until Day 21 of pregnancy. At slaughter on Day 27, 14 of the 20 pigs (8 GnRHa and 6 Control) were pregnant, and 6 were nonpregnant (3 and 3, respectively). Five nonpregnant gilts exhibited estrus (vulva swelling and back-pressure induced standing reflex) between Days 19 and 22. In the pregnant pigs, the mean (± SE) numbers of CLs were 17.0 ± 0.8 (GnRHa) and 19.6 ± 1.6 (Control), and the number of fetuses was 11.6 ± 2.3 and 12.8 ± 2.3, respectively, indicating early losses of 37 and 21%. There was no difference between the pregnant GnRHa-treated and Control animals. In the nonpregnant gilts, the mean number of CLs was in the range of pregnant gilts (15.3 ±
2.3).
Luteinizing hormone (LH)
There was an influence of treatment (P=0.03) and of time and treatment by time interaction (P<0.01) on LH release, but not of pregnancy. The present analyses of samples from the caval vein on Day 12 revealed that the LH concentration increased in all GnRHatreated animals for approximately 4 h, reaching a maximum after 1-2 h (Fig. 1A) .
On Days 11, 13, 15 and 17, one to three pulses of LH release were detected in both the GnRHa-treated and Control pigs during 6-h periods of intensive bleeding (Table 1 ; Fig. 2A, B) . In the pregnant gilts, the LH pulse amplitude decreased (P<0.05) on Days 13 to 17 in both groups compared with Day 11. Such a decrease was not observed in the nonpregnant animals. In the nonpregnant gilts, the LH pulse amplitude was higher (P<0.05) in the Controls than in the GnRHa-treated gilts on Days 13 and 15. Such difference was also obtained between pregnant and non-pregnant Control gilts. Differences were found with regard to basal LH concentrations (Table 1) . In all pregnant gilts, basal LH was lower (P<0.05) on Days 13 and 15. Furthermore, in the GnRHa-treated gilts, the basal LH levels were always elevated compared with the Controls (P<0.01). In the nonpregnant gilts, the basal LH level was not influenced on Days 11 to 15 in the GnRHa-treated animals, but was higher in the Controls on Day 13. Additionally, differences in basal LH were present between the pregnant and nonpregnant animals.
Follicle-stimulating hormone (FSH)
In regard to FSH, an influence of treatment, time and treatment by time interaction (P<0.01) was found. On Day 12, GnRHa induced an immediate and significant (P<0.01) FSH release, with the highest levels between 1 to 3 h after injection. The FSH level was not influenced in the Control animals (Fig. 1B) .
Progesterone (P4)
No differences were observed regarding mean P4 concentrations on Days 3 to 10 in the pregnant GnRHa-treated (26.9 ± 1.6 ng/ml) and Control gilts (29.9 ± 1.8 ng/ml) or in their nonpregnant counterparts (27.7 ± 1.6 and 24.8 ± 2.9 ng/ml, respectively).
On Day 12, daytime had an influence on the P4 concentration (0 vs. 300 min, P<0.01) in both the GnRHa-treated and Control gilts. However, the P4 concentration in the blood near to the ovary was not altered by GnRHa administration (Fig. 1C) .
The P4 concentration showed an episodic pattern in both groups on days with highly frequent sampling ( Table 2 ; Fig. 2C, D) . The mean (± SE) numbers of pulses were 3.6 ± 0.3 (GnRHa) and 3.5 ± 0.2 (Control), and were not affected by pregnancy. Maximum pulse values ranged up to 152.8 ng/ml. No differences in P4 pulse amplitude were obtained with regard to the day of pregnancy, treatment and pregnancy. Basal P4 decreased up to Day 17 in the pregnant GnRHa-treated and Control gilts and differed between the pregnant and nonpregnant Control gilts.
Furthermore, day of pregnancy influenced the P4 levels (P<0.01). P4 increased from Day 10 to Day 14 and subsequently decreased (Fig. 3) . However, no differences were obtained between the pregnant GnRHa-treated and Control gilts. The nonpregnant animals revealed typical lowering P4 concentrations after luteolysis (data not shown).
Estradiol (E2)
The mean (± SE) E2 concentrations on Day 12 were 97.2 ± 16.7 and 116.4 ± 16.4 pg/ml in the GnRHa and Control gilts, respectively. However, E2 did not differ between these groups throughout the sampling period (Fig. 1D) . Moreover, there was no influence of pregnancy.
Discussion
As LH is a key luteotrophic hormone in the pig [20] , the application of mammalian GnRH (GnRH-I) or its agonists during the early luteal phase or the attachment phase could result in an improvement of embryo survival. The effect by which additional GnRH may influence luteal function is thought to induce a significant increase in LH secretion for some hours. Indeed, the single GnRHa injection elevated the LH level for approximately 4 h in all treated animals. Maximum LH concentrations were higher than 2 ng/ml compared with basal concentrations of lower than 0.5 ng/ml. However, we unexpectedly found that the P4 release pattern was not affected by GnRHa treatment on Day 12, neither immediately after treatment nor on subsequent days. This seems to be in contrast to results of a comparable GnRHa treatment in heifers [21] and ewes Table 2 . Mean (± SE) number of P4 pulses/6 h, pulse amplitudes and basal concentrations (ng/ml) in the Vena cava caudalis of the GnRHa treated pregnant (n=8) and nonpregnant gilts (n=3) and pregnant (n=6) and nonpregnant Control gilts (n=3) on Days 11, 13, 15 and 17 of pregnancy Day of pregnancy 11 13 15 17 Pregnant gilts Number of P4 pulses GnRHa 4.0 ± 0.5 4.7 ± 0. [22] where the P4 concentrations in peripheral blood were elevated by peptide administration for some hours. We can only speculate that mono-ovulatory compared with multi-ovulatory CLs at early pregnancy may have diverse gonadotropin receptivity and/or steroid synthesis which could be responsible for such different P4 secretion. Additionally, there were no differences between the GnRHa-treated pregnant and nonpregnant animals (except the decrease of the P4 level by Days 15-17 in the nonpregnant gilts).
The GnRHa application did not alter the LH release pattern on consecutive days in the pregnant and nonpregnant gilts. Both the mean number of LH pulses during periods with intensive blood sampling on Days 13, 15 and 17 and the LH pulse frequency were not affected compared with the pattern on Day 11 (before treatment) and with that of the controls on all days. The differences obtained between the pregnant and nonpregnant gilts should be interpreted cautiously due to the limited number of nonpregnant animals. Basal LH was decreased on Days 13 and 15 in the pregnant animals of both treatments, but was higher in the GnRHatreated animals. So far, we do not have any explanation about the mechanisms of the difference between pregnant and nonpregnant animals.
In our previous study with a long-acting GnRH agonist in depot formulation [16] , we argued that episodic release of LH may not be as crucial for the maintenance of CL function and pregnancy as the mean or basal level of LH secretion because the altered LH secretion pattern did not affect the peripheral P4 level. Although the basal LH level in the present study was increased in the GnRHatreated pregnant gilts, the P4 level was not influenced. Whether or not only a threshold level of LH (the amount of which we do not know) is sufficient to maintain P4 secretion is still speculation. A study in ovariectomized gilts immunized against GnRH revealed that high GnRH pulses increase LH release [23] . The absence of high LH pulses in our study may argue that a temporal increase in LH may not be sufficient to increase P4 levels. Furthermore, the existence of two theca interna regions expressing the same steroidogenic enzymes but submitting to different hormone controls has been demonstrated [24] . These two regions and the cells of granulosa origin revealed distinct patterns of LH receptivity during CL development. To what extent the quality of the CLs in pregnant and nonpregnant gilts influence the obtained differences remains speculative. In the present study, we found an individual P4 release pattern during the 6-h intensive samplings on Days 11, 13, 15 and 17. This release was characterized by numerous episodic spikes, with absolute values two to three times higher than the basal concentrations. Such pulse-like P4 secretion has been previously found in cyclic gilts [14] . However, both the number of P4 pulses and the pulse amplitude did not differ between the GnRHa-treated and Control gilts, and between the pregnant and nonpregnant gilts. The P4 pulse number was considerably (up to four times) higher than the number of LH pulses. The episodic P4 secretion pattern from the ovary seems to be affected additionally by other, to our knowledge unknown, mechanisms. The basal P4 concentrations near to the ovary were always two to three times higher than reported in the periphery [16] ; however, the basal P4 was not affected by GnRHa treatment. This supports the relative autonomy of early CL function in the pig [25, 26] . Also, in most species P4 production is not under such acute stimulatory control of the pituitary as other endocrine glands [27] .
Previously, it was shown that there is an increase in P4 secretion in utero-ovarian blood between Days 14-18 of pregnancy [28] . However, our present data estimating P4 in the caval vein and those reported from peripheral blood collection [13, 14] do not confirm such a P4 increase. It has also been suggested that the P4 level on Days 2 and 3 of pregnancy influences conceptus development [29] . Our data did not find a relation between the P4 concentration on Day 3 and pregnancy outcome. The mean P4 concentration in the circulation near the ovary was similar in the GnRHa-treated and Control gilts (16.6 ± 3.9 vs. 19.9 ± 4.2 ng/ml), as was the number of fetuses in the pregnant animals (12.8 vs. 11.6).
Similar to LH, GnRHa also stimulated FSH release on Day 12 of pregnancy, but not secretion of E2. Whether or not FSH contributes to influence luteal function remains speculation. If we were to accept previous reports that steroid treatments in pigs [8, 9] or GnRH in horses [30, 31] benefit pregnancy outcome, other routes of GnRH mediation could also be evident, such as those influencing processes of uterine estrogen synthesis [32] , endometrial angiogenesis, utero-ovarian counter-current transfer [33] and P4 dependent immunomodulation [34, 35] . Furthermore, direct effects of GnRH on ovarian luteal cells [36] and on uterine tissues mediated by extrapituitary receptors should be recognized [37, 38] . Likewise, the induced LH secretion might affect the production of prostaglandins and steroids after binding to specific uterine receptors [39] [40] [41] . As recently shown, members of the pregnancyassociated glycoproteins (PAGs) are obviously involved in luteoprotective mechanisms by competitive binding to uterine and luteal gonadotropin receptors [42] .
However, our present study did not confirm the initial hypothesis that additional GnRHa application could alter ovarian steroid secretion and favorably support early embryo development and pregnancy outcome. 
